COR
Cencora, Inc.341.72
-8.60-2.45%
Dec 16, 4:00:03 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q1 '26
Reaffirms core strength, OneOncology details
Q&A largely reaffirmed prepared remarks' upbeat tone, with Cleary clarifying US healthcare solutions' 21% operating income growth stemmed from specialty strength despite oncology customer loss—ex-RCA and OneOncology, core performance hit long-term guide highs amid tough comps. Management detailed OneOncology's $30 million other-income benefit and 92% ownership, neutral to FY2026 EPS, while pausing buybacks to deleverage. International dip tied to manufacturer price timing in one developing market, offset by global specialty logistics volume gains. MSO synergies like clinical trials and revenue cycle drew praise; IRA negotiations preserved gross profits. Core ops hold firm.
Key Stats
Market Cap
66.29BP/E (TTM)
42.93Basic EPS (TTM)
7.96Dividend Yield
0.01%Recent Filings
8-K
8-K
Shareholders approve directors, pay
Cencora shareholders at the March 5, 2026 Annual Meeting elected all 11 director nominees, including Werner Baumann and Lori J. Ryerkerk, with strong support exceeding 95% 'for' votes in each case despite some opposition. They approved fiscal 2025 executive pay on an advisory basis (156.9M for vs. 11.4M against) and ratified Ernst & Young as auditors for fiscal 2026 (165.7M for). All proposals passed decisively.
8-K
MWI merges with Covetrus
Cencora signed a definitive agreement on February 17, 2026, to merge its MWI Animal Health unit with Covetrus at a $3.5B enterprise value. It gets $1.25B cash, $800M preferred units, and $1.45B common units for 34.3% ownership in the combined entity. Closing awaits regulatory nods. Cencora reaffirms FY2026 guidance, excluding the deal.
8-K
Cencora closes $3B notes
Cencora closed a $3.0 billion senior notes offering on February 13, 2026, issuing tranches maturing 2029-2056 at rates from 3.950% to 5.650%. Proceeds repay debt from its OneOncology acquisition, with leftovers for general purposes. Notes rank equally with existing unsecured debt. Refinancing locks in terms.
8-K
Prices $3B notes to repay loan
Cencora priced $3B in senior notes—$500M 3.950% due 2029, $500M 4.250% due 2030, $500M 4.600% due 2033, $1B 4.900% due 2036, $500M 5.650% due 2056—on February 10, 2026, expecting $2.98B net proceeds to repay its $3B 364-Day Term Loan funding the OneOncology acquisition. Closing set for February 13. Refinances short-term debt elegantly.
IPO
Website
Employees
Sector
Industry
BAX
Baxter International Inc.
19.05-0.48
CAH
Cardinal Health, Inc.
197.89-2.07
CI
The Cigna Group
276.11-1.04
CNC
Centene Corporation
38.97-1.48
COSM
Cosmos Health Inc.
0.50+0.09
CVS
CVS Health Corporation
78.29-1.40
MCK
McKesson Corporation
809.96-13.05
OMI
Owens & Minor, Inc.
3.10+0.09
VTRS
Viatris Inc.
11.46-0.20
WST
West Pharmaceutical Services, I
266.44-5.42